3 recruiting, 3 terminated, 2 active not recruiting, 2 completed. 12 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Recruiting 3, Terminated 3, Active not recruiting 2, Completed 2, Not yet recruiting 2 |
| Phase 2 | 4 | Active not recruiting 2, Recruiting 1, Terminated 1 |
Follow Hydroxydaunomycin: new trials by email Literature Review of Hydroxydaunomycin trials Research Report on Hydroxydaunomycin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients Biospecimen Collection, Computed Tomography, Cyclophosphamide - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 1 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 20 | 2026-12-08 | 2026-07-20 |
| Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma Biospecimen Collection, Cisplatin, Computed Tomography - Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 16 | 2026-10-30 | 2026-09-03 |
| Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | Phase 1 | Recruiting | City of Hope Medical Center | 20 | 2025-12-16 | 2026-06-05 |
| Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | OHSU Knight Cancer Institute | 40 | 2024-06-13 | 2026-07-07 |
| Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma Bone Marrow Biopsy, Cyclophosphamide, Doxorubicin - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 1 / Phase 2 | Active not recruiting | University of Washington | 33 | 2023-01-26 | 2026-10-30 |
| Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma Polatuzumab Vedotin, Rituximab, Prednisone - Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | University of Washington | 56 | 2020-10-27 | 2026-10-02 |
| PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer Biopsy, Cisplatin, Doxorubicin - Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8 | Phase 1 | Recruiting | City of Hope Medical Center | 49 | 2020-08-21 | 2026-08-26 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer Celecoxib, Cyclophosphamide, Doxorubicin - Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 | Phase 1 | Completed | Roswell Park Cancer Institute | 9 | 2019-12-06 | 2023-09-11 |
| Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia Etoposide, Doxorubicin, Vincristine - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma | Phase 1 | Completed | University of Washington | 24 | 2019-09-24 | 2023-07-06 |
| Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer Cyclophosphamide, Doxorubicin, Laboratory Biomarker Analysis - Breast Inflammatory Carcinoma, Locally Advanced Breast Carcinoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 34 | 2018-02-19 | 2026-02-12 |
| Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies Capecitabine, Carboplatin, Cyclophosphamide - Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC v8 | Phase 1 | Terminated | M.D. Anderson Cancer Center | 221 | 2015-06-26 | 2025-06-04 |
Lymphoma, Large B-Cell, Diffuse (4) · Breast Neoplasms (3) · Neoplasm Metastasis (3) · Ovarian Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Anemia (1) · Appendiceal Neoplasms (1) · Blast Crisis (1) · Breast Carcinoma In Situ (1) · Burkitt Lymphoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Fallopian Tube Neoplasms (1) · Hematologic Neoplasms (1)
University of Washington (3) · City of Hope Medical Center (2) · M.D. Anderson Cancer Center (2) · OHSU Knight Cancer Institute (2) · Jonsson Comprehensive Cancer Center (1) · National Cancer Institute (NCI) (1) · Roswell Park Cancer Institute (1)
United States (11)
Aung Naing, MD (1) · Christina Poh (1) · Lara Davis, MD (1) · Mustafa Raoof, MD (1) · Naseem Esteghamat (1) · Rachel Layman, MD (1) · Ryan Cassaday (1) · Ryan Lynch (1) · Shipra Gandhi (1) · Stephen D. Smith (1) · Stephen E Spurgeon (1) · Sven De Vos (1) · Thanh H Dellinger, MD (1)
PMID 33909232, PMID 34562230, PMID 34965890, PMID 36521030, PMID 37129197, PMID 38722664, PMID 39816915, PMID 39863139, PMID 39945382, PMID 40802906, PMID 41116969
P30CA033572 (2), UL1TR001412 (1), UM1CA186717 (1)